Form 4: BioXcel Therapeutics Executive Sells Shares After Vesting of Restricted Stock Units
SEC Form 4
Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, sold shares of common stock following the vesting of restricted stock units.
Summary
- Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, acquired 21,250 shares of common stock on September 17, 2024, due to the vesting of performance-based restricted stock units (PSUs).
- The performance conditions for these PSUs were met, and the shares became issuable on October 1, 2024.
- Rodriguez then sold 6,863 shares on October 3, 2024, at a weighted average price of $0.55 per share, with prices ranging from $0.5500 to $0.5515.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Rodriguez directly owns 23,770 shares of BioXcel Therapeutics.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing simply reports transactions. The use of a 10b5-1 plan suggests the sales were pre-planned and not necessarily indicative of a negative outlook.
Industry Context
Insider trading activity is always closely watched by investors. The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a common practice to avoid accusations of trading on inside information. However, the market may still react to insider sales, especially in smaller companies like BioXcel Therapeutics.
Stakeholder Impact
- Shareholders may react to the insider selling activity, although the existence of a 10b5-1 plan mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Rule 10b5-1 trading plan adopted by Javier Rodriguez |
| 2024-09-17 | Performance conditions met for 21,250 PSUs, shares acquired |
| 2024-10-01 | 21,250 shares of common stock became issuable to the Reporting Person |
| 2024-10-03 | 6,863 shares sold at $0.55 average price |
Keywords
BioXcel Therapeutics, BTAI, Javier Rodriguez, Form 4, insider trading, restricted stock units, Rule 10b5-1, stock sale, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.